NAGLU, Recombinant, Human (NAG, UFHSD1, Alpha-N-acetylglucosaminidase, N-acetyl-alpha-glucosaminidase)
Human lysosomal A-N-acetylglucosaminidase is a hydrolase that catalyses the removal of terminal A-N-acetylglucosamine residues from heparan sulfate and heparin. Defects in this gene are the cause of mucopolysaccharidosis type IIIB (MPS-IIIB), also known as Sanfilippo syndrome B. Mucopolysaccharidosis types IIIA, C, and D are caused by mutations in other genes involved in the lysosomal degradation of heparan sulfate. Continuous lysosomal accumulation of heparan sulfate results in the clinical onset of disease, which is typified by severe central nervous system degeneration. Mucopolysaccharidosis type III differs from other mucopolysaccharidoses in that patients usually exhibit mild somatic changes with minimal skeletal abnormalities.
Recombinant protein corresponding to Met1-Trp743 from human NAGLU fused to 6X His-Tag at C-terminal, expressed in CHO cell line. UniProt Accession: P54802.
Specific Activity
~900pmol/min/ug
Biological Activity
Measured by its ability to hydrolyze 4-Nitrophenyl-N-acetyl-a-D-glucosaminide.
Storage and Stability
May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 6 months after receipt at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
Source
Recombinant, CHO cells
Purity
≥95% by SDS-PAGE under reducing conditions.
Form
Supplied as a liquid in 25mM Tris, 150mM sodium chloride. BSA free.
Important Note
This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
